Cargando…

Prediction of the responsiveness to pharmacological chaperones: lysosomal human alpha-galactosidase, a case of study

BACKGROUND: The pharmacological chaperones therapy is a promising approach to cure genetic diseases. It relies on substrate competitors used at sub-inhibitory concentration which can be administered orally, reach difficult tissues and have low cost. Clinical trials are currently carried out for Fabr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Andreotti, Giuseppina, Guarracino, Mario R, Cammisa, Marco, Correra, Antonella, Cubellis, Maria Vittoria
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2010
Materias:	Methodology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016270/ https://www.ncbi.nlm.nih.gov/pubmed/21138548 http://dx.doi.org/10.1186/1750-1172-5-36

Ejemplares similares

Fabry_CEP: a tool to identify Fabry mutations responsive to pharmacological chaperones
por: Cammisa, Marco, et al.
Publicado: (2013)

Therapy of Fabry disease with pharmacological chaperones: from in silico predictions to in vitro tests
por: Andreotti, Giuseppina, et al.
Publicado: (2011)

Drug Repositioning for Fabry Disease: Acetylsalicylic Acid Potentiates the Stabilization of Lysosomal Alpha-Galactosidase by Pharmacological Chaperones
por: Monticelli, Maria, et al.
Publicado: (2022)

A thermodynamic assay to test pharmacological chaperones for Fabry disease()
por: Andreotti, Giuseppina, et al.
Publicado: (2014)

Identification of an Allosteric Binding Site on Human Lysosomal Alpha-Galactosidase Opens the Way to New Pharmacological Chaperones for Fabry Disease
por: Citro, Valentina, et al.
Publicado: (2016)

Identification and analysis of conserved pockets on protein surfaces
por: Cammisa, Marco, et al.
Publicado: (2013)

Challenging popular tools for the annotation of genetic variations with a real case, pathogenic mutations of lysosomal alpha-galactosidase
por: Cimmaruta, Chiara, et al.
Publicado: (2018)

Curcumin Has Beneficial Effects on Lysosomal Alpha-Galactosidase: Potential Implications for the Cure of Fabry Disease
por: Monticelli, Maria, et al.
Publicado: (2023)

Drug repositioning can accelerate discovery of pharmacological chaperones
por: Hay Mele, Bruno, et al.
Publicado: (2015)

Pharmacological Chaperones: A Therapeutic Approach for Diseases Caused by Destabilizing Missense Mutations
por: Liguori, Ludovica, et al.
Publicado: (2020)

Misfolding of Lysosomal α-Galactosidase a in a Fly Model and Its Alleviation by the Pharmacological Chaperone Migalastat
por: Braunstein, Hila, et al.
Publicado: (2020)

β-Glucose-1,6-Bisphosphate Stabilizes Pathological Phophomannomutase2 Mutants In Vitro and Represents a Lead Compound to Develop Pharmacological Chaperones for the Most Common Disorder of Glycosylation, PMM2-CDG
por: Monticelli, Maria, et al.
Publicado: (2019)

The Large Phenotypic Spectrum of Fabry Disease Requires Graduated Diagnosis and Personalized Therapy: A Meta-Analysis Can Help to Differentiate Missense Mutations
por: Citro, Valentina, et al.
Publicado: (2016)

Taming molecular flexibility to tackle rare diseases
por: Cubellis, Maria Vittoria, et al.
Publicado: (2015)

Looking for protein stabilizing drugs with thermal shift assay
por: Andreotti, Giuseppina, et al.
Publicado: (2015)

The New Pharmacological Chaperones PBXs Increase α-Galactosidase A Activity in Fabry Disease Cellular Models
por: Besada, Pedro, et al.
Publicado: (2021)

Synthesis of a New β-Galactosidase Inhibitor Displaying Pharmacological Chaperone Properties for GM1 Gangliosidosis
por: Clemente, Francesca, et al.
Publicado: (2022)

Protein structural features predict responsiveness to pharmacological chaperone treatment for three lysosomal storage disorders
por: Woodard, Jaie, et al.
Publicado: (2021)

Carnitine is a pharmacological allosteric chaperone of the human lysosomal α-glucosidase
por: Iacono, Roberta, et al.
Publicado: (2021)

Overexpression of human alpha-galactosidase A results in its intracellular aggregation, crystallization in lysosomes, and selective secretion
Publicado: (1992)

Autophagy-lysosome pathway associated neuropathology and axonal degeneration in the brains of alpha-galactosidase A-deficient mice
por: Nelson, Michael P, et al.
Publicado: (2014)

Immunocytochemical localization of lysosomal beta-galactosidase in rat liver
Publicado: (1983)

Assessment of Gene Variant Amenability for Pharmacological Chaperone Therapy with 1-Deoxygalactonojirimycin in Fabry Disease
por: Lukas, Jan, et al.
Publicado: (2020)

Biochemical phenotype of a common disease-causing mutation and a possible therapeutic approach for the phosphomannomutase 2-associated disorder of glycosylation
por: Andreotti, Giuseppina, et al.
Publicado: (2013)

Treating lysosomal storage diseases with pharmacological chaperones: from concept to clinics
por: Parenti, Giancarlo
Publicado: (2009)

Quantitative digital in situ senescence-associated β-galactosidase assay
por: Shlush, Liran I, et al.
Publicado: (2011)

Mechanistic Insights into the Chaperoning of Human Lysosomal-Galactosidase Activity: Highly Functionalized Aminocyclopentanes and C-5a-Substituted Derivatives of 4-epi-Isofagomine
por: Weber, Patrick, et al.
Publicado: (2020)

A Pharmacogenetic Approach to Identify Mutant Forms of α-Galactosidase A that Respond to a Pharmacological Chaperone for Fabry Disease
por: Wu, Xiaoyang, et al.
Publicado: (2011)

Heterodimerization of Two Pathological Mutants Enhances the Activity of Human Phosphomannomutase2
por: Andreotti, Giuseppina, et al.
Publicado: (2015)

Tuning protein folding in lysosomal storage diseases: the chemistry behind pharmacological chaperones
por: Pereira, David M., et al.
Publicado: (2018)

Coformulation of a Novel Human α-Galactosidase A With the Pharmacological Chaperone AT1001 Leads to Improved Substrate Reduction in Fabry Mice
por: Xu, Su, et al.
Publicado: (2015)

High Throughput Screening for Inhibitors of Alpha-Galactosidase
por: Motabar, Omid, et al.
Publicado: (2010)

Bioconversion of Beet Molasses to Alpha-Galactosidase and Ethanol
por: Álvarez-Cao, María-Efigenia, et al.
Publicado: (2019)

Why does SARS-CoV-2 hit in different ways? Host genetic factors can influence the acquisition or the course of COVID-19
por: Monticelli, Maria, et al.
Publicado: (2021)

Lysosomal lipid alterations caused by glucocerebrosidase deficiency promote lysosomal dysfunction, chaperone-mediated-autophagy deficiency, and alpha-synuclein pathology
por: Navarro-Romero, Alba, et al.
Publicado: (2022)

Co-administration With the Pharmacological Chaperone AT1001 Increases Recombinant Human α-Galactosidase A Tissue Uptake and Improves Substrate Reduction in Fabry Mice
por: Benjamin, Elfrida R, et al.
Publicado: (2012)

A mutant of phosphomannomutase1 retains full enzymatic activity, but is not activated by IMP: Possible implications for the disease PMM2-CDG
por: Citro, Valentina, et al.
Publicado: (2017)

Conformational Response to Ligand Binding in Phosphomannomutase2: INSIGHTS INTO INBORN GLYCOSYLATION DISORDER
por: Andreotti, Giuseppina, et al.
Publicado: (2014)

Congenital disorders of glycosylation: narration of a story through its patents
por: Monticelli, Maria, et al.
Publicado: (2023)

Pitfalls in methods to study colocalization of nanoparticles in mouse macrophage lysosomes
por: Moreno-Echeverri, Aura Maria, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_9tg52rs6uub5702r4ft3304shu